[1]延国威,王晓忠,范灵芝,等.和血柔肝方治疗慢性乙型肝炎肝纤维化临床研究[J].中国中医药信息杂志,2019,26(8):24-29.[doi:10.3969/j.issn.1005-5304.2019.08.006]
 YAN Guowei,WANG Xiaozhong,FAN Lingzhi,et al.Clinical Study on Hexue Rougan Prescription in Treatment of Liver Fibrosis Induced by Chronic Hepatitis B[J].zhongguo zhongyiyao xinxi zazhi,2019,26(8):24-29.[doi:10.3969/j.issn.1005-5304.2019.08.006]
点击复制

和血柔肝方治疗慢性乙型肝炎肝纤维化临床研究

参考文献/References:

[1] WANG F S, FAN J G, ZHANG Z, et al. The global burden of liver disease:the major impact of China[J]. Hepatology,2014,60(6):2099-2108.
[2] EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015,63(1):237-264.
[3] LIM J K, FLAMM S L, SINGH S, et al. American gastroenterological association institute guideline on the role of elastography in the evaluation of liver fibrosis[J]. Gastroenterology,2017, 152(6):1536-1543.
[4] SINGH S, MUIR A J, DIETERICH D T, et al. American gastroenterological association institute technical review on the role of elastography in chronic liver diseases[J]. Gastroenterology,2017,152(6):1544-1577.
[5] 郭峰,王晓忠,马燕,等.基于复杂网络的曾斌芳治疗慢性乙型肝炎用药规律研究[J].中国中医药信息杂志,2017,24(2):94-97.
[6] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015版)[J].中华肝脏病杂志,2015,23(12):888-905.
[7] 曹建彪,陈永平,成军,等.瞬时弹性成像技术(TE)临床应用专家共识(2015年)[J].中国肝脏病杂志(电子版),2015,7(2):12-18.
[8] 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中国肝脏病杂志(电子版),2010,2(4):54-59.
[9] TERRAULT N A, LOK A S, MCMAHON B J, et al. Update on prevention, diagnosis, and treatment and of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.
[10] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:143-151.
[11] KEMP W. ALA expert consensus recommendations for the use of TE in chronic viral hepatitis[J]. Gastroenterol Hepatol,2015, 30(3):453-462.
[12] 王家駹,李绍白.肝脏病学(第3版)[M].北京:中国医药科技出版社, 2013:621-627.
[13] 罗小闯.近30年肝纤维化中医证候及方药规律分析[J].中医学报, 2015,30(6):891-894.
[14] 徐列明.中医药抗肝纤维化疗效评价的探索[J].临床肝胆病杂志, 2017,33(5):825-828.
[15] 张轻舟.肝纤维化病名中医传统历史文献研究[J].内蒙古中医药, 2016,35(4):132-134.
[16] 胡希恕.胡希恕据证分类法[N].中国中医药报,2014-01-16(004).

相似文献/References:

[1]李珊,蔡锐,伍参荣.加味四逆散对血吸虫病小鼠肝纤维化相关因子表达的影响[J].中国中医药信息杂志,2011,18(2):41.[doi:10.3969/j.issn.1005-5304.2011.02.017]
 LI Shan,CAI Rui,WU Can-rong.Effect of Modified Sini Powder on Expression of Liver Fibrosis Related Factors in Schistosomiasis Mice[J].zhongguo zhongyiyao xinxi zazhi,2011,18(8):41.[doi:10.3969/j.issn.1005-5304.2011.02.017]
[2]郭晓平.双虎清肝颗粒联合苦参素对乙型肝炎病毒感染后肝纤维化指标的干预作用[J].中国中医药信息杂志,2008,15(2):71.
 [J].zhongguo zhongyiyao xinxi zazhi,2008,15(8):71.
[3]徐波,陆茵,吴家明,等.姜黄素抗肝纤维化分子机制研究进展[J].中国中医药信息杂志,2008,15(3):90.
 [J].zhongguo zhongyiyao xinxi zazhi,2008,15(8):90.
[4]范荣国,王安莲.苦参素胶囊联合安络化纤丸防治慢性乙型肝炎肝纤维化临床观察[J].中国中医药信息杂志,2008,15(5):71.
 [J].zhongguo zhongyiyao xinxi zazhi,2008,15(8):71.
[5]姚立,余静,李珏.丹参软肝饮对肝纤维化大鼠肝功能及肾素-血管紧张素-醛固酮系统的影响[J].中国中医药信息杂志,2011,18(4):34.[doi:10.3969/j.issn.1005-5304.2011.04.014]
 YAO Li,YU Jing,LI Jue.Influence of Danshen Ruangan Yin on Liver Fibrosis and RAAS of Rats[J].zhongguo zhongyiyao xinxi zazhi,2011,18(8):34.[doi:10.3969/j.issn.1005-5304.2011.04.014]
[6]刘江凯.百令胶囊治疗肝炎后肝纤维化临床观察[J].中国中医药信息杂志,2011,18(10):76.[doi:10.3969/j.issn.1005-5304.2011.10.033]
 [J].zhongguo zhongyiyao xinxi zazhi,2011,18(8):76.[doi:10.3969/j.issn.1005-5304.2011.10.033]
[7]李晓杰,车景超.中药抗肝纤维化研究进展[J].中国中医药信息杂志,2007,14(9):94.
 [J].zhongguo zhongyiyao xinxi zazhi,2007,14(8):94.
[8]张秋云,刘绍能,李媛娥.从痰论治肝纤维化探讨[J].中国中医药信息杂志,2007,14(11):86.
 [J].zhongguo zhongyiyao xinxi zazhi,2007,14(8):86.
[9]李亮,缪英年,月辰,等.平肝汤抗大鼠肝纤维化的实验研究[J].中国中医药信息杂志,2005,12(4):27.
 LI Liang,Miao Ying-nian,YUE Cheng,et al.Experimental Study on the Effects of Pinggan Tang on Liver Fibrosis[J].zhongguo zhongyiyao xinxi zazhi,2005,12(8):27.
[10]徐国良.中西医结合治疗慢性乙型肝炎肝纤维化36例[J].中国中医药信息杂志,2006,13(2):57.
 [J].zhongguo zhongyiyao xinxi zazhi,2006,13(8):57.

备注/Memo

基金项目:国家自然科学基金(81760832);中国肝炎防治基金会王宝恩肝纤维化研究基金(WBE20181031);新疆维吾尔自治区中医民族医药科技人才培养计划项目(20160315)

更新日期/Last Update:

2019-07-15